A lipid-lowering agent. Reversibly inhibits HMG-COA reductase, inhibits the cholesterol synthesis at the stage of mevinolinic acid and moderately reduces its intracellular concentration. The indications for the drug use include: primary hypercholesterolemia mainly of IIa and IIb types, under the ineffective diet treatment in patients with increased risk of coronary atherosclerosis, hypercholesterolemia combined with hypertriglyceridemia; prevention of coronary artery disease. The drug decreases the risk of myocardial infarction, the need for revascularization of the myocardium, deaths from cardiovascular system diseases.

Tricor - is a hypolipidemic agent, has an uricosuric and antiplatelet effect. In combination with diet therapy, the drug is prescribed for a long-term treatment, the effectiveness of which must be periodically checked by determining serum lipid levels.